Glucagon-like peptide-1 receptor controls exocytosis in chromaffin cells by increasing full-fusion events.
Cell Rep · 2021
Last updated 2026-05-28A synthetic GLP-1 drug called exendin-4 was found to increase the release of stress hormones from adrenal cells in two ways: after 24 hours, it boosted hormone production by 20%, and after just 20 minutes, it changed how hormones are released by switching from a partial-release process to a full-release process.
AI summary of the abstract below.
| Journal | Cell Rep, 2021 |
|---|---|
| Citations | 9 |
| Relative citation ratio | 0.68 |
| NIH percentile | 38 |
| Molecules | — |
Abstract
Agonists for glucagon-like-peptide-1 receptor (GLP-1R) are currently used for the treatment of type 2 diabetes and obesity. Their benefits have been centered on pancreas and hypothalamus, but their roles in other organ systems are not well understood. We studied the action of GLP-1R on secretions of adrenal medulla. Exendin-4, a synthetic analog of GLP-1, increases the synthesis and the release of catecholamines (CAs) by increasing cyclic AMP (cAMP) production, without apparent participation of cAMP-regulated guanine nucleotide exchange factor (Epac). Exendin-4, when incubated for 24 h, increases CA synthesis by promoting the activation of tyrosine hydroxylase. Short incubation (20 min) increases the quantum size of exocytotic events by switching exocytosis from partial to full fusion. Our results give a strong support to the role of GLP-1 in the fine control of exocytosis.
Verbatim abstract via PubMed 34433018 ↗